Peptides DB

Research-centric peptide and protocol reference hub

Best Peptides for Energy: Mitochondrial and Metabolic Support

Peptides studied for energy, mitochondrial function, and exercise capacity — NAD+, MOTS-c, AICAR, SS-31, SLU-PP-332 — with what each does and what's realistic.

By PeptidesDB EditorialPublished Jun 18, 20264 min read

The peptides studied for energy and mitochondrial function are NAD+ (and precursors NMN/NR), MOTS-c, AICAR, SS-31 (Elamipretide), L-Carnitine, and the newer SLU-PP-332. Effect sizes vary widely; NAD+ has the strongest human evidence for biomarker shifts; SLU-PP-332 has dramatic animal data but no human trials yet. None of these is a stimulant — they target the underlying cellular machinery, not the acute alertness pathway. This ranking covers what each does and what to expect.

For the bare hub see /peptides/category/energy and /peptides/category/metabolic.

Quick verdict table

Mechanism Best for Evidence
NAD+ (or NMN/NR) Coenzyme; sirtuin / mitochondrial function Age-related energy decline Strongest human
MOTS-c Mitochondrial peptide Exercise capacity, metabolic support Animal + limited human
SS-31 (Elamipretide) Cardiolipin protection Mitochondrial dysfunction Phase 2/3 in primary mito diseases
AICAR (Acadesine) AMPK activator Fatty-acid oxidation Animal + some clinical
L-Carnitine Fatty-acid shuttle Endurance, energy substrate Established
SLU-PP-332 Pan-ERR agonist Exercise mimetic (animal) No human data

The major options

1. NAD+ (and precursors NMN, NR)

The most evidence-supported "cellular energy" intervention. NAD+ declines with age across nearly every tissue; restoring it via oral NMN, NR, or IV NAD+ raises measured NAD+ levels. Downstream effects (sirtuin function, mitochondrial energy production, DNA repair) are mechanistically real; the clinical effects on subjective energy are more variable.

Pattern: Oral NMN 500 mg daily or NR 300 mg daily, continuous. IV NAD+ 500–1000 mg weekly to monthly.

NAD+ research profile.

2. MOTS-c

Mitochondrial-derived peptide. Animal data shows improved exercise capacity, insulin sensitivity, and metabolic markers. Human data limited but emerging.

Pattern: 5–10 mg SC weekly or biweekly during 4–8 week cycles.

MOTS-c research profile.

3. SS-31 (Elamipretide)

Cardiolipin-targeted mitochondrial protective peptide. Phase 2/3 trials in primary mitochondrial diseases (Barth syndrome) show measurable functional improvements; broader anti-fatigue use is mechanism-justified but with less direct human data.

Pattern: 5–10 mg SC daily during 4–8 week cycles.

SS-31 research profile.

4. AICAR (Acadesine)

AMPK activator. Increases fatty-acid oxidation; mimics some effects of exercise on metabolic gene expression in animal models. Human use is limited and primarily in research settings.

AICAR research profile.

5. L-Carnitine

Amino-acid derivative that shuttles long-chain fatty acids into mitochondria for oxidation. Established nutritional / clinical use. The energy effect is real for users with low baseline carnitine (vegetarians, certain medical conditions); less pronounced in users with normal baseline.

Pattern: Oral 1–3 g daily, or IV 2–4 g per infusion for clinical indications.

L-Carnitine research profile.

6. SLU-PP-332

Synthetic pan-ERR agonist; "exercise mimetic" in animal models. No published human data. Strong rodent endurance data; clinical translation is the unknown.

See SLU-PP-332 explained for the full evidence-vs-enthusiasm discussion.

SLU-PP-332 research profile.

What's NOT in this ranking

  • Stimulant-class compounds (modafinil, caffeine analogs, etc.). Different mechanism; not peptides; not the scope of this site.
  • Generic "B-complex injections" marketed for energy. Useful for specific deficiencies; not peptides.
  • Methylene blue and similar mitochondrial-adjacent small molecules. Outside scope.

A defensible energy-support protocol

For a user with measurable fatigue patterns not explained by an underlying medical condition:

  1. Rule out the medical causes first. Thyroid, anemia, sleep apnea, depression, low testosterone, vitamin deficiencies. These are not solved by peptides.
  2. Foundational lifestyle. Sleep schedule, training, sun exposure, social rhythm, caffeine cycling.
  3. Then layer in:
    • NAD+ precursor (oral NMN 500 mg daily) — continuous.
    • Optional MOTS-c during periods of high physical demand.
    • Optional SS-31 if measurable mitochondrial dysfunction (e.g., elevated lactate at low workloads, family history of mitochondrial disease).

Most users will not need anything beyond the NAD+ precursor for general energy support.

What this category will and won't do

Will:

  • Modest improvement in subjective energy in some users.
  • Measurable shifts in mitochondrial-function biomarkers.
  • Support for exercise capacity over multi-week timelines.

Won't:

  • Produce immediate, stimulant-like alertness.
  • Fix fatigue rooted in medical conditions (thyroid, anemia, depression, etc.).
  • Substitute for sleep.

Where to go from here